Publications
See a complete PubMed list of publications by Stephan Targan, MD.
Selected Key Publications
- Jacob N, Jacobs JP, Kumagai K, Ha CWY, Kanazawa Y, Lagishetty V, Altmayer K, Hamill AM, Von Arx A, Sartor RB, Devkota S, Braun J, Michelsen KS, Targan SR, Shih DQ. Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. Muscosal Immunol. 2018 Sep;11(5):1466-1476. https://www.nature.com/articles/s41385-018-0055-y.
- Workman MJ, Gleeson JP, Troisi EJ, Estrada HQ, Kerns SJ, Hinojosa CD, Hamilton GA, Targan SR, Svendsen CN, Barrett RJ. Enhanced utilization of induced pluripotent stem cell-derived human intestinal organoids using microengineered chips. Cell Mol Gastroenterol Hepatol. 2017 Dec 29;5(4):669-677.e2. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2352345X1730187X.
- Gonsky R, Fleshner P, Deem RL, Biener-Ramanujan E, Li D, Potdar AA, Bilsborough J, Yang S, McGovern DPB, Targan SR. Association of ribonuclease T2 gene polymorphisms with decreased expression and clinical characteristics of severity in Crohn’s disease. Gastroenterology. 2017 Jul;153(1):219-232. https://www.sciencedirect.com/science/article/pii/S0016508517354124
- Li D, Silverberg MS, Haritunians T, Dubinsky MC, Landers C, Stempak JM, Milgrom R, Guo X, Chen YD, Rotter JI, Taylor KD, McGovern DP, Targan SR. TNFRSF1B is associated with ANCA in IBD. Inflamm Bowel Dis. 2016 Jun;22(6):1346-1352. https://academic.oup.com/ibdjournal/article/22/6/1346/4561936.
- Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, Pothoulakis C, Koon HW, Targan SR. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol. 2014 Nov;7(6)1492-1503. https://www.nature.com/articles/mi201437
- Barrett R, Zhang X, Koon HW, Vu M, Chang JY, Yeager N, Nguyen MA, Michelsen KS, Berel D, Pothoulakis C, Targan SR, Shih DQ. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol. 2012 Feb;180(2):636-649. https://www.sciencedirect.com/science/article/pii/S0002944011010182.
- Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ, Derkowski C, McGovern DP, Rotter JI, Targan SR. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLOS ONE. 2009;4(3):e4719. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004719.
- Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008 Aug;135(2):552-567. https://www.sciencedirect.com/science/article/pii/S0016508508007798.
- Targan SR, Feagan B, Fedorak R, Lashner B, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007 May;132(5):1672-1683. https://www.sciencedirect.com/science/article/pii/S0016508507005380.
- Prehn JL, Mehdizadeh S, Landers, CS, Luo X, Cha SC, Wei P, Targan SR. Potential role for TL1A, the new TNF-family member and potent costimulatory of IFN-gamma, in mucosal inflammation. Clin Immunol. 2004 Jul;112(1):66-77. https://www.sciencedirect.com/science/article/pii/S1521661604000555
- Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology. 200 May;120(6):1347-1355. https://www.sciencedirect.com/science/article/pii/S001650850119428X.
- Gonsky R, Deem RL, Bream JH, Lee DH, Young HA, Targan SR. Mucosa-specific Targets for regulation of IFN-gamma expression: lamina propria T cells use different cis-elements than peripheral blood T cells to regulate transactivation of IFN-gamma expression. J Immunol. 2000 Feb 1;164(3):1399-1407. http://www.jimmunol.org/content/164/3/1399.long.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease: Crohn’s disease cA2 study group. N Engl J Med. 1997 Oct 9;337(15):1029-1035. https://www.nejm.org/doi/full/10.1056/NEJM199710093371502.
- Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA Class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest. 1993 Aug;92(2):1080-1084. https://www.jci.org/articles/view/116613.
- Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990 Aug;86(2):202-210. https://www.sciencedirect.com/science/article/pii/S0091674905800673.
Contact the Targan Lab
110 N. George Burns Road
Davis Building, Room D4063
Los Angeles, CA 90048